According to the firm, infectious-disease research advancements could be applied to discovering treatments for millions of hepatitis patients globally.
Gilead says launching generic versions of its pricey hepatitis C drugs more than a decade prior to patent expiries will more closely align product list prices with their cost.
The European Patent Office has upheld protection relating to Gilead’s costly Hepatitis C drug Sovaldi, which Médecins du Monde claims prevents patients from receiving affordable treatment.
KMT Hepatech is expanding its services with the PXB-Mouse – a humanized liver chimeric mouse model for drug discovery and development – following a strategic investment from PhoenixBio late last year.
Inadequate record keeping at Merck & Co.’s contract manufacturer has delayed the European launch of its hepatitis C drug Zepatier (elbasvir and grazoprevir).
The US FDA has rescinded Breakthrough Therapy designation of a second HCV treatment, but Bristol-Myers Squibb says submission timelines for daclatasvir will not be affected.
New hepatitis C drugs produced by Gilead, Janssen and AbbVie contributed to a first quarter spike in revenue for AmeriSourceBergen’s Pharmaceutical Distribution business.
Gilead and AbbVie’s exclusive deals with payers CVS and Express Scripts could help cut the cost of the new class of treatments for America’s three million Hepatitis C sufferers.
Abbvie’s multi-ingredient HCV treatment has been approved in the US, and following an exclusive deal with Express Scripts, could lead to a pricing war with Gilead.
Gilead says its hepatitis C combination drug Harvoni will deliver significant healthcare savings in the long-term despite its $1,150 (€885) a pill price tag.
The market opportunity for each Indian drugmakers granted a license to manufacture Gilead’s hepatitis C drug Sovaldi could be worth over $600m, an analyst has calculated.
Gilead has granted seven Indian drugmakers licenses to produce generic versions of its $1,000 a pill drug Sovaldi to increase access to hepatitis C medicines in 91 developing countries.
Merck & Co. says the $3.85bn (€2.8bn) acquisition of Idenix will springboard its oral hepatitis C programme but according to an analyst is unlikely to threaten Gilead’s $1,000 pill Sovaldi.
Esoterix Clinical Trials Services has forged a strategic alliance with the David H. Murdock Research Institute (DHMRI) to provide its clients with access to enhanced assay development services.
A long-acting biologic being co-developed by Novartis to treat
chronic hepatitis C virus (HCV) has triggered a $40m (€29.3m)
milestone for its development partner after clearing Phase II
trials in April.
Vertex Pharmaceuticals has released early results on its
first-in-class hepatitis C drug that show it has the potential to
shorten treatment times for those suffering from the hard-to-treat
genotype-1.
Bayer Diagnostics and Innogenetics have launched an assay that
allows genotyping for the Hepatitis C Virus (HCV), permitting
broader identification of HCV genotypes with improved accuracy, not
possible by current HCV genotyping products.
Roche took the opportunity at the American Association for the
Study of Liver Diseases (AASLD) meeting to disclose the results of
its hepatitis C polymerase inhibitor, which exhibited viral
reductions greater than current polymerase...
Celera Genomics announces its new test that is used for genotyping
of the hepatitis C virus (HCV) has obtained regulatory approval for
commercial sale in Europe, signifying the first real-time test for
genotyping the HCV virus to...
A new polymer drug delivery technology developed by Dutch firm
OctoPlus has cleared Phase I trials for the first time, showing
promise in a new controlled release treatment of chronic hepatitis
C.
Intermune and Array BioPharma have agreed to extend and expand
their current Hepatitis C (HCV) drug discovery collaboration. The
main area of focus, protease inhibitors, represents a promising
class of drugs for HCV because of its...
Novartis has announced the formation of a collaboration with Anadys
Pharmaceuticals to develop Hepatitis C (HCV) and hepatitis B (HBV)
therapeutics in a deal worth at least $570 million (€466 million).
Intermune has announced the results of preclinical data on the
specificity and tolerability of two potent and selective small
molecule inhibitors of the hepatitis C virus (HCV). The findings
are significant, as they have previously...
Vertex Pharmaceuticals have announced the latest results that
indicate the investigational oral hepatitis C virus (HCV) protease
inhibitor VX-950 was well tolerated and demonstrated potent
antiviral activity in a Phase Ib clinical...
Pfizer is to acquire Idun Pharmaceuticals in an agreement, which
includes a new technology platform with potential applications in
liver disease, inflammation and cancer.
Pharmasset of the US could receive funding of $168 million
(€131.8m) in upfront and milestone payments - with the prospect of
receiving more - after licensing its preclinical hepatitis C drug
programme to Swiss drug giant Roche.
Swiss biopharmaceuticals company BioPartners has filed its first
application in Europe for a generic version of interferon alpha, a
biological drug. If approved, the 'biosimilar' could be on the
market as early as next year.
In response to recent news regarding patent litigation surrounding
its drug ribavirin, biopharmaceutical company Ribapharm announced
this week that it believes its patent position to be unchanged by
Schering-Plough's recent action...